Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis, and peritoneal mesothelioma.
about
Preoperative and surveillance MR imaging of patients undergoing cytoreductive surgery and heated intraperitoneal chemotherapyThen and now: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspectiveOxaliplatin-based versus irinotecan-based hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis from appendiceal and colorectal cancer: a retrospective analysis.A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trialBEV-IP: Perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis.Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapyAntitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism.Systematic review on the efficacy of multimodal treatment of sarcomatosis with cytoreduction and intraperitoneal chemotherapy.Pathological response to neoadjuvant chemotherapy: a new prognosis tool for the curative management of peritoneal colorectal carcinomatosis.Diagnostic Laparoscopy in the Pre-operative Assessment of Patients Undergoing Cytoreductive Surgery and HIPEC for Peritoneal Surface Malignancies.Selection of patients and staging of peritoneal surface malignanciesEvaluation of intracavitary mitoxantrone and carboplatin for treatment of carcinomatosis, sarcomatosis and mesothelioma, with or without malignant effusions: A retrospective analysis of 12 cases (1997-2002)*.Surveillance MR imaging is superior to serum tumor markers for detecting early tumor recurrence in patients with appendiceal cancer treated with surgical cytoreduction and HIPEC.Intraperitoneal cytokine level in patients with peritoneal surface malignancies. A study of the RENAPE (French Network for Rare Peritoneal Malignancies).Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis.Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma.Peritoneal cancer treatment with CYP2B1 transfected, microencapsulated cells and ifosfamide.Laparoscopy as a useful selection tool for patients with prior surgery and peritoneal metastases suitable for multimodality treatment strategies.Ultrasound criteria and guided fine-needle aspiration diagnostic yields in small animal peritoneal, mesenteric and omental disease.Surgery for peritoneal mesothelioma.Applications of hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer.Diagnostic value of whole-body MRI with diffusion-weighted sequence for detection of peritoneal metastases in colorectal malignancy.
P2860
Q26768400-4E2148EA-4E95-44B6-BAD2-6D05C6A43C55Q26768408-7C6B28A8-E443-4C53-888B-131D781135ECQ34491336-273AC3BC-0F79-417C-B403-500E7FA29FD8Q34580450-F818E0DC-42F1-4A75-AC15-C962B680FF1AQ35870363-E81763E3-B8B8-4CFB-9560-7153BCDCF348Q37090867-991D15C3-C707-47FF-9D43-A7ED930AC10DQ37591581-6095B9C9-5167-4131-A928-9F640CB345BBQ37779034-136AC583-8F2D-492E-9974-B13B1E482015Q38199370-96165C87-5A95-48D6-A58F-1188DF3132F3Q38804709-4AE55319-6CCF-4587-8AA6-2B717CCA4DC8Q41132530-B4C02CDF-F2FE-46B2-A192-89B9E9635C7DQ43276501-721A1469-BBC9-45F9-ADA0-5346901BF0D7Q43735451-F8E9C26B-DEEB-4DCD-8261-E6570220492BQ44649132-A7EDC229-EB3D-4C8F-9E3E-875A65E29A27Q45730190-5DFC6571-A485-4FCD-8DB8-2886AC771347Q46255077-ECBD1883-DC9F-4482-B140-DE5A9927E96EQ46647061-FB1DC44A-93F5-434C-934C-6AE808DFB395Q47197797-1CCF4E6C-3F1D-4E80-8801-87A228CE2D38Q51201835-E0214939-DE73-420E-812F-57D7BB69EBCDQ51485434-4AC9B0C8-864B-43E4-BC49-8C6B1C241BEBQ51825453-652703C7-4BA8-47F7-BFBD-CB692AFE0C75Q55385444-93EEE9BA-8E09-4737-9FC0-AE0540B83637
P2860
Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis, and peritoneal mesothelioma.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Quantitative prognostic indica ...... , and peritoneal mesothelioma.
@ast
Quantitative prognostic indica ...... , and peritoneal mesothelioma.
@en
type
label
Quantitative prognostic indica ...... , and peritoneal mesothelioma.
@ast
Quantitative prognostic indica ...... , and peritoneal mesothelioma.
@en
prefLabel
Quantitative prognostic indica ...... , and peritoneal mesothelioma.
@ast
Quantitative prognostic indica ...... , and peritoneal mesothelioma.
@en
P1476
Quantitative prognostic indica ...... s, and peritoneal mesothelioma
@en
P2093
François Noël Gilly
P304
P356
10.1016/S1055-3207(03)00037-1
P577
2003-07-01T00:00:00Z